Investigational drug · Phase 3
Corabotase
Also called: IPN10200
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Glabellar Lines, Spasticity, Moderate to Severe Upper Facial Lines.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
7
Any phase or sponsor naming "Corabotase"
First trial start
2021
Apr 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Corabotase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Glabellar Lines
- Spasticity
- Moderate to Severe Upper Facial Lines
- Episodic Migraine
- Chronic Migraine
- Cervical Dystonia
Approved drugs for the same conditions: Migraine · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Corabotase" as an intervention, largest first.
- A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT07435428 · 1,305 participants · Start Feb 18, 2026 · Primary completion Sep 28, 2026
Drug: Corabotase; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Los Angeles, California; Newport Beach, California; Pasadena, California · 60 sites in all
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial LinesPivotal-lookingActive, not recruiting
IpsenIndustry
NCT04821089 · 727 participants (planned) · Start Apr 6, 2021 · Primary completion Aug 19, 2027
Drug: Corabotase; IPN10200 Placebo and 1 more · For: Moderate to Severe Upper Facial Lines
Sites: Antibes, France; Lyon, France; Paris, France · 10 sites in all
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT06625060 · 670 participants · Start Oct 10, 2024 · Primary completion Oct 31, 2027
Drug: Corabotase; Corabotase dose A and 1 more · For: Episodic Migraine; Chronic Migraine
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 162 sites in all
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT07427797 · 309 participants · Start Feb 27, 2026 · Primary completion Aug 12, 2026
Drug: Corabotase; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Birmingham, Alabama; Glendale, Arizona; Scottsdale, Arizona · 23 sites in all
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.Pivotal-lookingRecruiting
IpsenIndustry
NCT04752774 · 240 participants (planned) · Start Apr 29, 2021 · Primary completion Mar 30, 2029
Drug: Corabotase; Placebo and 1 more · For: Spasticity
Sites: Downey, California; Overland Park, Kansas; Farmington Hills, Michigan · 81 sites in all
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the EyebrowsPivotal-lookingRecruiting
IpsenIndustry
NCT07779252 · 160 participants (planned) · Start Aug 25, 2026 · Primary completion Apr 10, 2028
Drug: Corabotase; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Guangzhou, China; Changsha, China; Nanjing, China · 9 sites in all
- A Study of IPN10200 for the Treatment of Cervical Dystonia in AdultsPivotal-lookingRecruiting
IpsenIndustry
NCT06937931 · 132 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 26, 2027
Drug: Corabotase · For: Cervical Dystonia
Sites: Tucson, Arizona; Fountain Valley, California; Loma Linda, California · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Moderate to Severe Glabellar Lines
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.